We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » SPA in Hand, EpiCept to Conduct Additional Trial for Ceplene
SPA in Hand, EpiCept to Conduct Additional Trial for Ceplene
November 10, 2010
EpiCept has reluctantly agreed to conduct another Phase III trial to support a new drug application (NDA) for its acute myeloid leukemia (AML) candidate Ceplene under a special protocol assessment (SPA) after a recent meeting with the FDA.